ACUR - Acura Pharmaceuticals, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
12/30/2015
Total Revenue
279
410
2,966
4,464
8,587
Cost of Revenue
-
0
128
451
656
Gross Profit
-
410
2,838
4,013
7,931
Operating Expenses
Research Development
1,422
1,759
3,721
4,028
2,608
Selling General and Administrative
2,060
2,566
4,342
6,516
8,994
Total Operating Expenses
3,482
4,325
8,063
10,544
11,602
Operating Income or Loss
-3,203
-3,915
-5,225
-6,531
-3,671
Interest Expense
410
395
596
893
1,157
Total Other Income/Expenses Net
-
296
-
36
-161
Income Before Tax
-3,136
-3,842
-5,817
-7,388
-4,989
Income Tax Expense
0
0
-135
0
-
Income from Continuing Operations
-3,136
-3,842
-5,682
-7,388
-4,989
Net Income
-3,136
-3,842
-5,682
-7,388
-4,989
Net Income available to common shareholders
-3,136
-3,842
-5,682
-7,388
-4,989
Reported EPS
Basic
-
-
-0.36
-0.62
-0.46
Diluted
-
-
-0.36
-0.62
-0.46
Weighted average shares outstanding
Basic
-
-
15,903
11,870
10,796
Diluted
-
-
15,903
11,870
10,796
EBITDA
-
-3,167
-4,927
-6,495
-3,832